TP53 and acute myeloid leukemia: Another retrospective study by Aldoss et al. [68], including 32 adult patients all with TP53-mutated AML (16 R/R and 15 newly diagnosed) treated with VEN + HMA, reported a global response rate of 52% (n = 16), with 7 patients experiencing CR and 9 CRi (38% CR/CRi rate in R/R).